NOS2 and susceptibility to pneumonia measurement: Gene therapy with hBD-3 reduces pneumonia, possibly through increased levels of IFN-γ and inducible nitric oxide synthase (iNOS) expression and the chemoattraction of lymphocytes and macrophages [133].